Business Wire

NTHU

28.10.2021 11:02:08 CEST | Business Wire | Press release

Share
NTHU and DAICEL of Japan to Jointly Develop Revolutionary Desktop Chemical Plant

National Tsing Hua University (NTHU) and the well-known Japanese chemical company DAICEL announce a five-year joint project to integrate an innovative microfluidic system developed by scholar Kitamori Takehiko into the chemical manufacturing industry today. Total investment in the project is 450 million Japanese yen (approximately NT$110 million), and its potential to reduce energy consumption while lowering the production of carbon and waste is expected to set a new standard for sustainability in the chemical industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005388/en/

Prof. Kitamori, a world-renowned pioneer in microfluidic and nanofluidic technology and the former vice president of the University of Tokyo, has been serving as the Yushan Honorary Chair Professor of the Institute of Nanoengineering and Microsystems, Department of Power Mechanical Engineering at NTHU since 2020. Building on his previous research conducted at the University of Tokyo, he has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card and capable of combining thousands of microfluidic chips simultaneously, making it possible to create a “desktop chemical plant.”

Kitamori explained that it can be quite difficult to instantaneously mix several large barrels of chemicals with different temperatures and reaction speeds, and there may even be an explosion if the materials are not handled carefully. Thus the preferred way of blending chemicals is by passing it through a microchannel, which makes it possible to precisely control the amount of raw materials used, as well as the mixing sequence and conditions, thereby optimizing the quality of the final product.

Kitamori said that the aim of the project is to reduce the size of chemical production equipment, so that what is currently produced by a factory measuring 20 x 20 meters can be miniaturized into a system only two square meters in size. What’s more, such a system would use less energy and materials, making it less expensive, and would also produce less carbon.

Years ago, when DAICEL president Ogawa Yoshimi heard about the microfluidic technology developed by Kitamori, he was deeply impressed, and is now highly pleased that DAICEL is going to integrate this innovative technology into its operations. He is also looking forward to cooperating with NTHU in introducing this epoch-making manufacturing process to the world, which he also sees as a way of promoting sustainability and the circular economy.

Dr. Fan-gang Tseng, Vice President and Director of Research and Development, NTHU, said that he is very optimistic about the future development of the microfluidic chemical plant. He pointed out that the adoption of this microfluidic process by DAICEL—one of the largest chemical companies in Japan—and by Taiwan’s many small and medium-sized chemical factories would constitute a revolutionary leap forward, and could lead to similar processes being applied by the semiconductor and biomedical industry.

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye